Cover Image
市場調查報告書

Ambit Biosciences Corporation:產品平台分析

Ambit Biosciences Corporation - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 224704
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
Ambit Biosciences Corporation:產品平台分析 Ambit Biosciences Corporation - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 36 Pages
簡介

Ambit Biosciences Corporation是開發針對癌症用小分子治療藥的生物醫藥品企業。

本報告提供Ambit Biosciences Corporation的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Ambit Biosciences Corporation的基本資料

Ambit Biosciences Corporation概要

  • 主要資訊
  • 企業資料

Ambit Biosciences Corporation:R&D概要

  • 主要的治療範圍

Ambit Biosciences Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Ambit Biosciences Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Ambit Biosciences Corporation:藥物簡介

  • quizartinib
  • AC-410
  • AC-430
  • AC-708

Ambit Biosciences Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ambit Biosciences Corporation:最近的開發平台趨勢

Ambit Biosciences Corporation:暫停中的計劃

Ambit Biosciences Corporation:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • AC-480

Ambit Biosciences Corporation:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04919CDB

Global Markets Direct's, 'Ambit Biosciences Corporation - Product Pipeline Review - 2014', provides an overview of the Ambit Biosciences Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ambit Biosciences Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ambit Biosciences Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ambit Biosciences Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ambit Biosciences Corporation's pipeline products

Reasons to buy

  • Evaluate Ambit Biosciences Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ambit Biosciences Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ambit Biosciences Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ambit Biosciences Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ambit Biosciences Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ambit Biosciences Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ambit Biosciences Corporation Snapshot
    • Ambit Biosciences Corporation Overview
    • Key Information
    • Key Facts
  • Ambit Biosciences Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Ambit Biosciences Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Ambit Biosciences Corporation - Pipeline Products Glance
    • Ambit Biosciences Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Ambit Biosciences Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ambit Biosciences Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Ambit Biosciences Corporation - Drug Profiles
    • quizartinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-410
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-430
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-708
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ambit Biosciences Corporation - Pipeline Analysis
    • Ambit Biosciences Corporation - Pipeline Products by Target
    • Ambit Biosciences Corporation - Pipeline Products by Route of Administration
    • Ambit Biosciences Corporation - Pipeline Products by Molecule Type
    • Ambit Biosciences Corporation - Pipeline Products by Mechanism of Action
  • Ambit Biosciences Corporation - Recent Pipeline Updates
  • Ambit Biosciences Corporation - Dormant Projects
  • Ambit Biosciences Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AC-480
  • Ambit Biosciences Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ambit Biosciences Corporation, Key Information
  • Ambit Biosciences Corporation, Key Facts
  • Ambit Biosciences Corporation - Pipeline by Indication, 2014
  • Ambit Biosciences Corporation - Pipeline by Stage of Development, 2014
  • Ambit Biosciences Corporation - Monotherapy Products in Pipeline, 2014
  • Ambit Biosciences Corporation - Out-Licensed Products in Pipeline, 2014
  • Ambit Biosciences Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Ambit Biosciences Corporation - Phase III, 2014
  • Ambit Biosciences Corporation - Phase II, 2014
  • Ambit Biosciences Corporation - Phase I, 2014
  • Ambit Biosciences Corporation - Preclinical, 2014
  • Ambit Biosciences Corporation - Pipeline by Target, 2014
  • Ambit Biosciences Corporation - Pipeline by Route of Administration, 2014
  • Ambit Biosciences Corporation - Pipeline by Molecule Type, 2014
  • Ambit Biosciences Corporation - Pipeline Products by Mechanism of Action, 2014
  • Ambit Biosciences Corporation - Recent Pipeline Updates, 2014
  • Ambit Biosciences Corporation - Dormant Developmental Projects,2014
  • Ambit Biosciences Corporation - Discontinued Pipeline Products, 2014
  • Ambit Biosciences Corporation, Other Locations

List of Figures

  • Ambit Biosciences Corporation - Pipeline by Top 10 Indication, 2014
  • Ambit Biosciences Corporation - Pipeline by Stage of Development, 2014
  • Ambit Biosciences Corporation - Monotherapy Products in Pipeline, 2014
  • Ambit Biosciences Corporation - Pipeline by Top 10 Target, 2014
  • Ambit Biosciences Corporation - Pipeline by Top 10 Route of Administration, 2014
  • Ambit Biosciences Corporation - Pipeline by Top 10 Molecule Type, 2014
  • Ambit Biosciences Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top